H.R. 5526 119th Congress
Biosimilar Red Tape Elimination Act
- Health
- Sponsor: Rep. Pfluger, August [R-TX-11]
- Congress.gov ↗
Latest action, Sep 19, 2025: Referred to the House Committee on Energy and Commerce.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
10 cosponsors
Sponsored by Rep. Pfluger, August [R-TX-11] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
4 D · 6 R
Referred to: House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
5 reports
ASSOCIATION OF ACCESSIBLE MEDICINES
MEHLMAN CONSULTING, INC.
5 reports
5 reports
THE BIOSIMILARS FORUM
THORN RUN PARTNERS
5 reports
4 reports
4 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
4 reports
4 reports
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC
COVINGTON & BURLING LLP
4 reports
4 reports
3 reports
THE CAMPAIGN FOR SUSTAINABLE RX PRICING
MEHLMAN CONSULTING, INC.
3 reports
AMGEN INC
TIBER CREEK GROUP
2 reports
The top 25 of 26 clients, by reports
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMGEN INC | 5 | $15.3M | Q4 2025 | Q3 2026 | yes | |
| ASSOCIATION OF ACCESSIBLE MEDICINES | MEHLMAN CONSULTING, INC. | 5 | $300K | Q4 2025 | Q3 2026 | yes |
| JOHNSON & JOHNSON SERVICES INC | 5 | $11.2M | Q4 2025 | Q3 2026 | yes | |
| THE BIOSIMILARS FORUM | THORN RUN PARTNERS | 5 | $500K | Q4 2025 | Q3 2026 | yes |
| AMERICAN COLLEGE OF RHEUMATOLOGY | 4 | $310K | Q4 2025 | Q3 2026 | yes | |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | 4 | $3.5M | Q4 2025 | Q2 2026 | yes | |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | WHITMER & WORRALL, LLC | 4 | $200K | Q4 2025 | Q2 2026 | yes |
| FRESENIUS KABI USA LLC | 4 | $2.0M | Q4 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | COVINGTON & BURLING LLP | 4 | $0 | Q3 2025 | Q3 2026 | yes |
| PRIME THERAPEUTICS | 4 | $460K | Q4 2025 | Q3 2026 | yes | |
| KAISER FOUNDATION HEALTH PLAN INC | 3 | $4.0M | Q1 2026 | Q3 2026 | yes | |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | MEHLMAN CONSULTING, INC. | 3 | $270K | Q1 2026 | Q3 2026 | yes |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 2 | $6.0M | Q2 2026 | Q3 2026 | yes | |
| AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2 | $510K | Q2 2026 | Q3 2026 | yes | |
| AMGEN INC | TIBER CREEK GROUP | 2 | $0 | Q2 2026 | Q3 2026 | yes |
| AMGEN, INC. | AVENUE SOLUTIONS | 2 | $0 | Q2 2026 | Q3 2026 | yes |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 2 | $560K | Q2 2026 | Q3 2026 | yes | |
| BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | 2 | $710K | Q2 2026 | Q3 2026 | yes | |
| NATIONAL TAXPAYERS UNION | 2 | $60K | Q4 2025 | Q2 2026 | yes | |
| AMGEN | SIGHTLINE ADVOCACY, LLC | 1 | $0 | Q4 2025 | Q4 2025 | yes |
| APOTEX CORP. | 1 | $730K | Q2 2026 | Q2 2026 | — | |
| CENCORA FKA AMERISOURCEBERGEN CORPORATION | HORIZON GOVERNMENT AFFAIRS | 1 | $50K | Q1 2025 | Q1 2025 | yes |
| HOUSE RX | FORBES-TATE | 1 | $0 | Q1 2025 | Q1 2025 | yes |
| NATIONAL ASSOCIATION OF SPECIALTY PHARMACY | POWERS PYLES SUTTER & VERVILLE, P.C. | 1 | $120K | Q1 2025 | Q1 2025 | yes |
| PFIZER INC. | 1 | $1.9M | Q2 2026 | Q2 2026 | yes |